Clinical medicine profile
Miocamycin
Therapeutic agent (verify pharmacological class)
- Route
- See product SmPC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Hypersensitivity to the active substance or excipients.
- Additional absolute contraindications are indication- and product-specific — consult SmPC.
Precautions
- Lactation, impaired hepatic func- tions.
- Do not give together with chloramphenicol, pregnancy especially first trimester, monitor prothrombin times during coumarin-type anti- coagulant concommitant therapy.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
0.91.8g daily in 2-3 divided doses. Children: 35-50mg/kg/day in divided doses.
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Use, effects & interactions
Indications
- An alternative for penicillin-allergic patients
- intestinal amoebiasis, chlamydial, mycoplasmal infections, URTI, LRTI, skin and soft tissue infections, gonococcal male urethritis and female pelvic infections, long term prophylaxis of rheumatic fever, early syphillis in penicillin allergic patients, tetanus, legionnaires disease.
Adverse effects
- Pseudomembranous colitis, GI disturbances, allergic reactions, reversible hearing loss, super-infections, ventricular arrythmias with prolonged QT interval, agranulocytosis, myasthe- nia-like syndrome, pancreatitis, Stevens-Johnson and toxic epidermal necrolysis, hepatic dysfunc- tions, fever.
Drug interactions
Open multi-drug checker ↗- It shows greater in vitro potency than erythromycin against Legionella pneumophila, Mycoplasma hominis, Ureaplasma urealyticum and erythromycin-resistant staphylococcal and streptococcal species.
- It however possesses poor overall activity against Haemophilus influenzae and Enterobacteriaceae
Mechanism & disposition
Binds to 50s sub-unit of the bacterial ribosome and inhibits bacterial protein synthesis by preventing attachment of aminoacyl transfer RNA to its acceptor site on the ribosome.
Read complete mechanism
Binds to 50s sub-unit of the bacterial ribosome and inhibits bacterial protein synthesis by preventing attachment of aminoacyl transfer RNA to its acceptor site on the ribosome. This prevents peptide bond formation by peptidyl transferase.
Product-specific
Product-specific
See product SmPC
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| Uncomplicated genital chlamydia | Afya Index / Retail Reference | tabs 600mg 12's | KES 1,456.00afya_index_book |
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.